FDA expands meningitis vaccine age range

Oct 18, 2007

The U.S. Food and Drug Administration has expanded the approved age range for Menactra, a bacterial meningitis vaccine.

Originally approved by the FDA in 2005 for use by people ages 11 to 55 years, it is now approved to include children ages 2 to 10 years.

Meningitis is a serious inflammation of the lining that surrounds the spinal cord and brain and can result in death or permanent injury.

Before Menactra's approval, Menomune was the only meningococcal vaccine available in the United States for use in children, ages 2 years and older. Both products are manufactured by Sanofi Pasteur Inc. of Swiftwater, Pa., and both offer protection against four groups of Neisseria meningitidis, the bacterium that can cause meningitis.

The Centers for Disease Control and Prevention recommends meningococcal vaccination for children ages 2 to 10 years who are at increased risk of meningococcal disease, such as those whose spleen has been removed; those with a medical condition that makes it difficult to fight infection; and those who expect to travel to areas where the disease is common.

Vaccination also is used to control outbreaks of bacterial meningitis.

Copyright 2007 by United Press International

Explore further: Questions over value of new antibiotics to tackle resistance

add to favorites email to friend print save as pdf

Related Stories

Applause triggers award for Meccanoid robot in Vegas

Jan 12, 2015

The open source robotic building platform, Meccanoid G15 KS from Spin Master, won top prize in a "Last Gadget Standing" showdown at CES on Thursday. Damon Poeter of PCMag described The Meccanoid G15 KS as ...

Current state of the American family

Oct 21, 2014

Most young Americans plan to get married someday, but more than 40 percent of births now occur outside marriage, and the American family itself has become far more diverse and varied.

Recommended for you

Questions over value of new antibiotics to tackle resistance

17 hours ago

In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they d ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.